adi CEO Paul Smith Joins IChemE Pharmaceutical Special Interest Group Executive Committee

We’re proud to share that our CEO, Paul Smith, has been appointed to the Executive Committee of the IChemE’s Pharmaceutical Special Interest Group.

This appointment recognises Paul’s proven leadership and strong track record in the pharmaceutical and engineering sectors. Committee members are carefully selected from a small group of senior professionals who have made significant contributions to the industry.

The Pharma Special Interest Group is part of the Institution of Chemical Engineers (IChemE) and represents over 5,000 professionals across the UK and Ireland. Its diverse membership includes chemists, chemical engineers, pharmacists, mechanical and electrical engineers, and others, all working together to address key challenges and opportunities in the pharmaceutical and bioprocess industries.

"I’m pleased to have been asked to join the Executive Committee of the Pharma Special Interest Group. The pharmaceutical and bioprocess industries are evolving quickly, and this group plays an important role in shaping what comes next. It’s also a great opportunity to connect with both current and future clients who are part of the network. With the launch of adi Life Sciences as our latest division, this couldn’t come at a better time. I’m looking forward to getting involved, sharing ideas, and representing adi Group, all with the goal of helping to engineer a better future for the industry." - Paul Smith, CEO

You can read more about the Pharma Special Interest Group and Paul’s role here.

Please join us in congratulating Paul on this great achievement.